SCHEMBL20183667

SCHEMBL20183667

CCn1c(=O)cc(C)c2cc(-n3c(-c4ccccc4)c[nH]c3=O)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAC2 P15153 1/20 0.41
RAC3 P60763 1/20 0.41
CDC42 P60953 1/20 0.41
RAC1 P63000 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 9/20 0.40
ALDH1A1 P00352 5/20 0.40
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PKM P14618 1/20 0.37
ADORA1 P30542 1/20 0.37
LMNA P02545 1/20 0.36
RCE1 Q9Y256 1/20 0.36
PGR P06401 1/20 0.36
GRIK2 Q13002 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20195108 0.83 ALDH1A1 (0.40) RAC2RAC3CDC42RAC1KMT2A
SCHEMBL20183683 0.81 KDM4E (0.40) RAC2RAC3CDC42RAC1KMT2A
SCHEMBL20183765 0.81 HTR6 (0.36) RAC2RAC3CDC42RAC1KMT2A
SCHEMBL20183815 0.81 GAA (0.40) RAC2RAC3CDC42RAC1KMT2A
SCHEMBL20183592 0.78 HTR6 (0.39) KDM4EPOLBHSD17B10L3MBTL1LMNA
SCHEMBL20183855 0.78 MEN1 (0.47) RAC2RAC3CDC42RAC1KMT2A
SCHEMBL20183876 0.77 TP53 (0.33) KDM4EALDH1A1HPGDMAPK1
SCHEMBL20183535 0.74 MAPT (0.33) KDM4EALDH1A1HPGDMAPTMAPK1
SCHEMBL20806222 0.74 GAA (0.40) KMT2AMEN1KDM4EALDH1A1HPGD
SCHEMBL17446075 0.73 ALDH1A1 (0.65) KMT2AMEN1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 RAC2 1731/4885RAC3 1617/4885CDC42 310/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 RAC2 3470/4885RAC3 3358/4885CDC42 876/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 RAC2 1731/4885RAC3 1617/4885CDC42 310/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 RAC2 3470/4885RAC3 3358/4885CDC42 876/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 RAC2 3502/4885RAC3 3522/4885CDC42 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.